Hilltop Holdings Inc. decreased its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 58.1% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 11,674 shares of the biopharmaceutical company’s stock after selling 16,209 shares during the quarter. Hilltop Holdings Inc.’s holdings in Bristol-Myers Squibb were worth $739,000 at the end of the most recent reporting period.
A number of other institutional investors also recently made changes to their positions in the stock. Sciencast Management LP purchased a new position in Bristol-Myers Squibb during the first quarter worth approximately $602,000. First Commonwealth Financial Corp PA lifted its position in Bristol-Myers Squibb by 211.8% during the first quarter. First Commonwealth Financial Corp PA now owns 11,281 shares of the biopharmaceutical company’s stock worth $714,000 after buying an additional 7,663 shares in the last quarter. Kovack Advisors Inc. lifted its position in Bristol-Myers Squibb by 9.4% during the first quarter. Kovack Advisors Inc. now owns 14,482 shares of the biopharmaceutical company’s stock worth $916,000 after buying an additional 1,239 shares in the last quarter. Arete Wealth Advisors LLC lifted its position in Bristol-Myers Squibb by 15.3% during the first quarter. Arete Wealth Advisors LLC now owns 12,828 shares of the biopharmaceutical company’s stock worth $811,000 after buying an additional 1,703 shares in the last quarter. Finally, Ancora Advisors LLC lifted its position in Bristol-Myers Squibb by 4.8% during the first quarter. Ancora Advisors LLC now owns 115,507 shares of the biopharmaceutical company’s stock worth $7,306,000 after buying an additional 5,331 shares in the last quarter. Hedge funds and other institutional investors own 71.37% of the company’s stock.
In other news, Director Dinesh C. Paliwal acquired 4,770 shares of the company’s stock in a transaction dated Monday, April 30th. The stock was acquired at an average cost of $52.40 per share, with a total value of $249,948.00. Following the completion of the purchase, the director now owns 8,027 shares of the company’s stock, valued at approximately $420,614.80. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.23% of the company’s stock.
Shares of Bristol-Myers Squibb opened at $54.80 on Friday, according to MarketBeat Ratings. Bristol-Myers Squibb Co has a twelve month low of $49.96 and a twelve month high of $70.05. The company has a quick ratio of 1.39, a current ratio of 1.52 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $87.66 billion, a PE ratio of 18.21, a PEG ratio of 1.40 and a beta of 0.95.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 26th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.09. Bristol-Myers Squibb had a return on equity of 37.56% and a net margin of 4.37%. The business had revenue of $5.19 billion during the quarter, compared to analysts’ expectations of $5.25 billion. During the same period in the previous year, the firm posted $0.84 earnings per share. The company’s revenue was up 5.4% on a year-over-year basis. research analysts anticipate that Bristol-Myers Squibb Co will post 3.43 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 1st. Stockholders of record on Friday, July 6th will be paid a $0.40 dividend. The ex-dividend date is Thursday, July 5th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.92%. Bristol-Myers Squibb’s payout ratio is presently 53.16%.
BMY has been the topic of a number of analyst reports. Jefferies Financial Group set a $70.00 price objective on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Friday, March 23rd. Argus reiterated a “buy” rating and set a $66.43 price objective (down previously from $75.00) on shares of Bristol-Myers Squibb in a research report on Wednesday, March 21st. William Blair reissued an “outperform” rating on shares of Bristol-Myers Squibb in a research note on Tuesday, April 17th. JPMorgan Chase & Co. set a $75.00 target price on Bristol-Myers Squibb and gave the stock an “overweight” rating in a research note on Tuesday, March 20th. Finally, TheStreet cut Bristol-Myers Squibb from a “b” rating to a “c+” rating in a research note on Thursday, March 8th. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $62.84.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.